

PRESS RELEASE

Villejuif, 1 April 2025

LAUNCH OF THE EUROPEAN PROGRAMME DOSELIA: ARTIFICIAL INTELLIGENCE IN THE SERVICE OF PAEDIATRIC RADIOTHERAPY

DOSELIA, a collaborative European research project involving leading institutions across Europe and coordinated by Gustave Roussy, aims to improve paediatric radiotherapy by reducing the long-term side effects of treatments. The initiative seeks to optimise care for young cancer patients by integrating cutting-edge technologies to better assess and limit healthy tissue exposure to radiation.

Every year, 35,000 children and adolescents in Europe are diagnosed with cancer, with a five-year survival rate exceeding 80%. In 2020, Europe had approximately 600,000 survivors of paediatric cancer, a number expected to continue rising.

Radiotherapy is a critical treatment for many childhood cancers, but it can have lasting side effects, affecting both nearby and distant healthy tissues.

According to epidemiological studies, one in five patients cured of paediatric cancer develops a second tumour before the age of 50, with a risk twice as high as that of the general population, even 40 years after the end of treatment. While genetic predisposition and certain chemotherapies can also increase the risk of secondary cancer, radiotherapy remains a significant risk factor. For example, cranial irradiation increases the long-term risk of developing a new brain tumour tenfold. Thoracic irradiation exposes female patients to a breast cancer risk comparable to that of women carrying a BRCA1 mutation. Moreover, the younger the age at radiation exposure, the higher the risk of developing leukaemia, breast cancer, brain tumours, and thyroid cancer.

Developing an AI Tool for Precision Radiotherapy

Current planning systems do not allow for precise estimation of radiation doses received at a distance from the treated area, complicating risk assessment and treatment optimisation. Coordinated by Charlotte Robert, a researcher at Gustave Roussy and associate professor in medical physics at Université Paris-Saclay, the DOSELIA project aims to address this challenge by using artificial intelligence to better model the patient's overall exposure to radiation and anticipate long-term risks.

"The main objective of this project is to develop a dosimetric modelling software based on artificial intelligence. This tool will enable precise evaluation of the doses received by the entire body in young patients undergoing radiotherapy treatment. All irradiations received by the patient during their care, including those related to the planning CT scan and the positioning images taken at each treatment session, will be considered. This project will also provide predictive models for the risk of secondary cancers in cured patients. Finally, this AI tool will

serve as a real clinical decision support system, enabling radiation oncologists to adjust treatment parameters based on each patient's profile, optimising the balance between therapeutic efficacy and side-effect reduction," explains Charlotte Robert.

Currently, precise whole-body dose assessments require time-consuming Monte Carlo simulations, which model the interaction of ionising radiation with biological tissues. However, these simulations require access to supercomputers and are not suitable for direct clinical use. DOSELIA's AI-driven approach aims to deliver comparable accuracy in a fraction of the time.

Validating Models with Real-World Data

To refine its predictions, DOSELIA will draw on data from the HARMONIC programme, a European project that follows cohorts of children and adolescents treated with photon or proton radiotherapy. Funded by the European Commission, HARMONIC collects clinical, dosimetric, and biological data. Thanks to this collaboration, DOSELIA will be able to utilise a unique European database to train and validate its algorithms on real-life data, ensuring greater accuracy in dose estimations and risk projections for future patients.

"Integrating the AI tool developed under the DOSELIA project into routine clinical practice could transform paediatric radiotherapy by providing a more detailed view of the doses received by the entire body. This approach will enable doctors to optimise each treatment to reduce healthy tissue exposure while maintaining maximum tumour control." (Institution's spokesperson)

Funding and Collaboration

DOSELIA has received €944,000 in funding from the European Union under the PIANOFORTE project (Grant no. LW Contract 2025-0019). PIANOFORTE, a Euratom-funded initiative, supports research to improve protection against ionising radiation in medical and environmental settings.

Project Partners:

- Gustave Roussy (France, Project Coordinator)
- French Alternative Energies and Atomic Energy Commission (France)
- French National Institute of Health and Medical Research (France)
- University of Caen (France)
- Centre François-Baclesse (France)
- Aarhus University (Denmark)
- Aarhus University Hospital (Denmark)
- Ludwig Maximilian University of Munich (Germany)
- West German Proton Therapy Centre Essen (Germany)
- University Hospital Essen (Germany)

This pan-European effort underscores the power of collaboration in advancing paediatric cancer care through innovation.



Co-funded by
the European Union

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not

necessarily reflect those of the European Union or the European Health and Digital Executive

Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.

About Gustave Roussy

Ranked first in France, first in Europe and fourth in the world, Gustave Roussy is a centre of global expertise entirely dedicated to patients living with cancer. The Institute is a founding pillar of the Paris-Saclay Cancer Cluster. Source of therapeutic innovations and diagnostic breakthroughs, the Institute welcomes nearly 50,000 patients each year, including 3,500 children and adolescents, and develops an integrated approach combining research, care and teaching. An expert in rare cancers and complex tumours, Gustave Roussy treats all cancers at all stages of life. It offers its patients personalised care that combines innovation and humanity, taking into account both care and the physical, psychological and social quality of life. With 4,100 employees at two sites, Villejuif and Chevilly-Larue, Gustave Roussy brings together the expertise essential for high-level cancer research; 40% of treated patients are included in clinical studies. To find out more about Gustave Roussy and follow the Institute's news: www.gustaveroussy.fr/en, [X](#), [Facebook](#), [LinkedIn](#), [Instagram](#).

PRESS CONTACT

GUSTAVE ROUSSY:

Claire Parisel - claire.parisel@gustaveroussy.fr - Tel. +33 1 42 11 50 59 - +33 6 17 66 00 26